TY - JOUR
T1 - Willingness to take multidrug-resistant tuberculosis (MDR-TB) preventive therapy among adult and adolescent household contacts of MDR-TB index cases
T2 - An international multisite cross-sectional study
AU - Suryavanshi, Nishi
AU - Murrill, Matthew
AU - Gupta, Amita
AU - Hughes, Michael
AU - Hesseling, Anneke
AU - Kim, Soyeon
AU - Naini, Linda
AU - Jones, Lynne
AU - Smith, Betsy
AU - Gupte, Nikhil
AU - Dawson, Rodney
AU - Mave, Vidya
AU - Meshram, Sushant
AU - Mendoza-Ticona, Alberto
AU - Sanchez, Jorge
AU - Kumarasamy, Nagalingeswaran
AU - Comins, Kyla
AU - Conradie, Francesca
AU - Shenje, Justin
AU - Fontain, Sandy Nerette
AU - Garcia-Prats, Anthony
AU - Asmelash, Aida
AU - Nedsuwan, Supalert
AU - Mohapi, Lerato
AU - Lalloo, Umesh
AU - Ferreira, Ana Cristina Garcia
AU - Okeyo, Elisha
AU - Swindells, Susan
AU - Churchyard, Gavin
AU - Shah, N. Sarita
N1 - Funding Information:
Financial support. This work was supported by the National Institute of Allergy Infectious Diseases of the National Institutes of Health with co-funding from the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), the National Institute of Mental Health (NIMH), all of the US National Institutes of Health (grant numbers UM1AI068634, UM1AI068636, UM1AI106701, UM1AI068632, UM1AI068616 and UM1AI106716) and by NICHD contract number HHSN275201800001I. M. T. M. received training support from the Johns Hopkins University Medical Scientist Training Program funded by the National Institute of General Medical Sciences (5T32GM007309-43) as well as the UJMT (US collaborating universities - University of North Carolina at Chapel Hill, Johns Hopkins University, Morehouse School of Medicine and Tulane University) Fogarty Global Health Fellowship (award number D43TW009340) funded by the Fogarty International Center; the National Institute of Neurological Disorders and Stroke; the National Heart, Lung and Blood Institute; and the National Institute Environmental Health Sciences of the NIH.
Publisher Copyright:
© The Author(s) 2019.
PY - 2020/2/1
Y1 - 2020/2/1
N2 - Background. Household contacts (HHCs) of individuals with multidrug-resistant tuberculosis (MDR-TB) are at high risk of infection and subsequent disease. There is limited evidence on the willingness of MDR-TB HHCs to take MDR-TB preventive therapy (MDR TPT) to decrease their risk of TB disease. Methods. In this cross-sectional study of HHCs of MDR-TB and rifampicin-resistant tuberculosis (RR-TB) index cases from 16 clinical research sites in 8 countries, enrollees were interviewed to assess willingness to take a hypothetical, newly developed MDR TPT if offered. To identify factors associated with willingness to take MDR TPT, a marginal logistic model was fitted using generalized estimating equations to account for household-level clustering. Results. From 278 MDR-TB/RR-TB index case households, 743 HHCs were enrolled; the median age of HHCs was 33 (interquartile range, 22-49) years, and 62% were women. HHC willingness to take hypothetical MDR TPT was high (79%) and remained high even with the potential for mild side effects (70%). Increased willingness was significantly associated with current employment or schooling (adjusted odds ratio [aOR], 1.83 [95% confidence interval {CI}, 1.07-3.13]), appropriate TB-related knowledge (aOR, 2.22 [95% CI, 1.23-3.99]), confidence in taking MDR TPT (aOR, 7.16 [95% CI, 3.33-15.42]), and being comfortable telling others about taking MDR TPT (aOR, 2.29 [95% CI, 1.29-4.06]). Conclusions. The high percentage of HHCs of MDR-TB/RR-TB index cases willing to take hypothetical MDR TPT provides important evidence for the potential uptake of effective MDR TPT when implemented. Identified HHC-level variables associated with willingness may inform education and counseling efforts to increase HHC confidence in and uptake of MDR TPT.
AB - Background. Household contacts (HHCs) of individuals with multidrug-resistant tuberculosis (MDR-TB) are at high risk of infection and subsequent disease. There is limited evidence on the willingness of MDR-TB HHCs to take MDR-TB preventive therapy (MDR TPT) to decrease their risk of TB disease. Methods. In this cross-sectional study of HHCs of MDR-TB and rifampicin-resistant tuberculosis (RR-TB) index cases from 16 clinical research sites in 8 countries, enrollees were interviewed to assess willingness to take a hypothetical, newly developed MDR TPT if offered. To identify factors associated with willingness to take MDR TPT, a marginal logistic model was fitted using generalized estimating equations to account for household-level clustering. Results. From 278 MDR-TB/RR-TB index case households, 743 HHCs were enrolled; the median age of HHCs was 33 (interquartile range, 22-49) years, and 62% were women. HHC willingness to take hypothetical MDR TPT was high (79%) and remained high even with the potential for mild side effects (70%). Increased willingness was significantly associated with current employment or schooling (adjusted odds ratio [aOR], 1.83 [95% confidence interval {CI}, 1.07-3.13]), appropriate TB-related knowledge (aOR, 2.22 [95% CI, 1.23-3.99]), confidence in taking MDR TPT (aOR, 7.16 [95% CI, 3.33-15.42]), and being comfortable telling others about taking MDR TPT (aOR, 2.29 [95% CI, 1.29-4.06]). Conclusions. The high percentage of HHCs of MDR-TB/RR-TB index cases willing to take hypothetical MDR TPT provides important evidence for the potential uptake of effective MDR TPT when implemented. Identified HHC-level variables associated with willingness may inform education and counseling efforts to increase HHC confidence in and uptake of MDR TPT.
KW - Contacts
KW - Drug resistance
KW - Preventive therapy
KW - Prophylaxis
KW - Tuberculosis
UR - http://www.scopus.com/inward/record.url?scp=85077950738&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85077950738&partnerID=8YFLogxK
U2 - 10.1093/cid/ciz254
DO - 10.1093/cid/ciz254
M3 - Article
C2 - 30919881
AN - SCOPUS:85077950738
SN - 1058-4838
VL - 70
SP - 436
EP - 445
JO - Clinical Infectious Diseases
JF - Clinical Infectious Diseases
IS - 3
ER -